HWA
MBRX icon

HCR Wealth Advisors’s Moleculin Biotech MBRX Stock Holding History

HCR Wealth Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7
Closed -$14K – 253
2020
Q2 		$14K Hold
7
– – ﹤0.01% 216
2020
Q1 		$9K Buy
+7
New +$11.9K ﹤0.01% 213

Other funds holding MBRX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return

HCR Wealth Advisors's MBRX Position: Q3 2020 in Review

HCR Wealth Advisors sold out of Moleculin Biotech (MBRX) in Q3 2020, closing a stake of 7 shares — an estimated $14K sold.

HCR Wealth Advisors first reported a position in MBRX in Q1 2020 and held it in 2 quarters. The position peaked at $14K in Q2 2020. 18 funds tracked by Wall St. Rank hold MBRX as of Q3 2020.

  • HCR Wealth Advisors reported no remaining Moleculin Biotech position as of Q3 2020 after selling out during the quarter.
  • HCR Wealth Advisors sold 7 Moleculin Biotech shares in Q3 2020, an estimated $14K.
  • HCR Wealth Advisors first reported a position in Moleculin Biotech in Q1 2020 and held it in 2 quarters.
  • HCR Wealth Advisors's Moleculin Biotech position peaked at $14K in Q2 2020.
  • 18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2020.

Based on HCR Wealth Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.